COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    A pilot study examining selinexor’s ability to overcome resistance in multiple myeloma patients who are refractory to lenalidomide-containing therapy.
Previous Study | Return to List | Next Study

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04519476
Recruitment Status : Not yet recruiting
First Posted : August 19, 2020
Last Update Posted : October 27, 2020
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):